Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET

Company Participants

Bruce Mackle - Managing Director, LifeSci Advisors

Steven Fruchtman - President and Chief Executive Officer

Michael Saunders - Interim Chief Medical Officer

Mark Guerin - Chief Operating Officer and Chief Financial Officer

Conference Call Participants

Joseph Pantginis - H.C. Wainwright

Ahu Demir - Ladenburg Thalmann

Robert LeBoyer - Noble Life Science Partners

Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Onconova Therapeutics First Quarter 2023 Financial Results and Business Update Conference Call. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a question-and-answer session. [Operator Instructions] As a reminder, this call is being recorded today, May 15, 2023.

At this time, I would like to turn the call over to Bruce Mackle of LifeSci Advisors. Please go ahead, Bruce.

Bruce Mackle

Thank you, operator, and welcome, everyone, to Onconova's first quarter 2023 financial results and business update conference call. Earlier this afternoon, Onconova issued a press release reporting its financial results and business progress. If you have not yet seen this press release, it is available in the Investors & Media section of the Company's website at onconova.com.

Following my introduction, we will hear from Onconova's President and CEO, Dr. Steve Fruchtman; Interim Chief Medical Officer; Dr. Michael Saunders; and Chief Operating Officer and Chief Financial Officer, Mark Guerin. Onconova's VP of Regulatory Affairs and Quality Assurance, Fred Frullo, will also be available during the Q&A session following the prepared remarks.

Before we begin, I would like to remind everyone that statements made during this conference call will include forward-looking statements under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties that can cause actual results to differ materially. Forward-looking statements speak only as of the date they are made as the underlying facts and circumstances may change. Except as required by law, Onconova disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances.

For more information on forward-looking statements, please review the disclaimer in today's press release and the risk factors in the Company's SEC filings.

With that, I will now turn the call over to Onconova's President and CEO, Dr. Steve Fruchtman.

Steven Fruchtman

Thanks, Bruce, and thanks to all for listening. Before we provide our update, I'd like to take a moment to remember our late Chief Medical Officer, Dr. Mark Gelder. Mark made many valuable contributions to Onconova and had a very distinguished career as a biomedical innovator and oncologist, dedicated advancing the care of patients with female reproductive cancers.